CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel⦠read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
$1.31
Price-13.30%
-$0.20
$20.296m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$31.564m
-
1y CAGR-
3y CAGR-
5y CAGR-$46.890m
-
1y CAGR-
3y CAGR-
5y CAGR-$3.04
-
1y CAGR-
3y CAGR-
5y CAGR-$20.310m
$31.202m
Assets$51.512m
Liabilities$18.734m
Debt60.0%
-0.5x
Debt to EBITDA$0.00
-
1y CAGR-
3y CAGR-
5y CAGR